ClinicalTrials.gg
Not yet recruitingNCT07900789Updated Oct 28, 2026

HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer

A Phase 3 interventional study of HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection and HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection in Systemic Treatment-naïve Pancreatic Cancer, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Newly registeredGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
825
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is being conducted To evaluate the efficacy of HRS-4642 in combination with gemcitabine plus nab-paclitaxel (AG) (± SHR-1316) versus standard therapy in participants, high-risk resectable/borderline resectable pancreatic cancer (HR-RPC/BRPC), based on Event-Free Survival (EFS).

02

Conditions studied

  • Systemic Treatment-naïve Pancreatic Cancer
03

In context

Pancreatic Neoplasms

3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,007 are open to participants now.

This study's planned enrollment of 825 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.

Browse Pancreatic Neoplasms studies →

Lead sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide , with a signed and dated IRB/EC-approved informed consent form (ICF), and willing and able to comply with the scheduled visits, treatment plan, examinations, and other protocol-required procedures.
  2. Aged between 18 and 75 years (inclusive) at the time of ICF signing; of either gender.
  3. performance status (ECOG PS) of 0 or 1.
  4. Expected survival of at least 6 months.
  5. or cytologically confirmed pancreatic cancer originating from the pancreatic ductal epithelium.
  6. High-risk resectable pancreatic cancer (HR-RPC) or borderline resectable pancreatic cancer (BRPC).
  7. At least one per (RECIST) Version 1.1.
  8. Adequate major organ function meeting the protocol-specified criteria.-

Exclusion criteria

Exclusion Criteria:

  1. Prior systemic therapy for pancreatic cancer, including chemotherapy or radiotherapy.
  2. Distant lesions confirmed by imaging.
  3. Has not recovered from the toxicity and/or complications of prior interventions to Grade ≤ 1 or the level specified in the inclusion/exclusion criteria.
  4. Currently has active disease or a history of autoimmune disease with potential recurrence.
  5. Received systemic therapy within 14 days prior to randomization.
  6. Known or suspected interstitial lung disease; or presence within 6 months prior to randomization of moderate-to-severe pulmonary diseases that may interfere with the detection or management of drug-related pulmonary toxicity or significantly impair respiratory function.
  7. Symptomatic moderate or severe ascites; uncontrolled or moderate-to-large pleural effusion or pericardial effusion.
  8. Gastrointestinal obstruction within 6 months prior to initiation of study treatment, or current signs and symptoms of gastrointestinal obstruction.
  9. bleeding episodes or a clear bleeding tendency within 6 months prior to randomization.
  10. Uncontrolled or severe cardiovascular/cerebrovascular disease, or arterial/venous thromboembolic events within 6 months prior to randomization; or arrhythmia, deep vein thrombosis, etc. requiring clinical intervention.
  11. Carotid ultrasound demonstrating ≥ 50% stenosis, or carotid plaques with ≥ 2 high-risk features.
  12. Diagnosis of any other within 5 years prior to randomization.
  13. Serious infection within 28 days prior to the first dose; or active infection requiring therapeutic intravenous antibiotics within 2 weeks prior to initiation of study treatment.
  14. Clinically significant acute or chronic pancreatitis.
  15. Active or active .
  16. Active pulmonary tuberculosis infection within 1 year prior to enrollment.
  17. History of immunodeficiency or organ transplantation.
  18. Active autoimmune disease requiring systemic treatment within 2 years prior to randomization.
  19. Administration of a within 28 days prior to randomization, or anticipated need for live attenuated vaccination during study treatment.
  20. Participation in any other clinical drug trial within 4 weeks or 5 half-lives (whichever is longer) of the last study drug administration prior to randomization.
  21. Major surgery (other than diagnostic procedure or ) within 28 days prior to randomization; invasive minor surgery within 7 days prior to the first dose; or presence of a non-healing wound.
  22. Known to any component of HRS-4642; or known severe hypersensitivity to any of the combination antitumor agents (including SHR-1316, gemcitabine, and nab-paclitaxel).
  23. Uncontrolled psychiatric illness, or known alcoholism, drug abuse, substance dependence, criminal detention, or other conditions that may interfere with completion of study procedures.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
825 participants (estimated)

Study arms

  • Experimental
    Experimental group 1: HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for I

    Drug: HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

  • Experimental
    Experimental group 2: HRS -4642+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

    Drug: HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

  • Active comparator
    Comparator group: Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

    Drug: Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

Interventions

  • DrugHRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

    Drug pages: KRAS G12D Inhibitor HRS-4642 · Adebrelimab · Gemcitabine · Paclitaxel

    HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

  • DrugHRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

    Drug pages: KRAS G12D Inhibitor HRS-4642 · Gemcitabine · Paclitaxel

    HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

  • DrugGemcitabine Hydrochloride for Injection+Paclitaxel for Injection

    Drug pages: Gemcitabine · Paclitaxel

    Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS) based on Independent Review Committee according to RECIST v1.1

    Time frame: From the beginning of randomization to the time of disease progression,about 14-20 months after first dose

Secondary outcomes

  1. The rates of pathological complete response (pCR)

    Assessed by the independent pathology center and the investigator

    Time frame: about 4-6 months after first dose

  2. major pathological response (mPR)

    Assessed by the independent pathology center and the investigator

    Time frame: about 4-6 months after first dose

  3. surgical resection rate

    Assessed by the investigator

    Time frame: about 4-6 months after first dose

  4. R0 resection rate

    Assessed by the investigator

    Time frame: about 4-6 months after first dose

  5. objective response rate (ORR)

    Assessed by the Independent Review Committee r and the investigator

    Time frame: From the beginning of randomization to the time of disease progression,about 14-20 months after first dose

  6. disease-free survival (DFS)

    Assessed by the Independent Review Committee and the investigator

    Time frame: From the beginning of randomization to the time of disease progression,about 14-20 months after first dose

  7. event-free survival (EFS)

    Assessed by the investigator

    Time frame: From the beginning of randomization to the time of disease progression,about 14-20 months after first dose

  8. overall survival (OS)

    Assessed by the investigator

    Time frame: From the beginning of randomization to the time of death,about 30 months after first dose

  9. The incidence and severity of adverse events (AEs)

    Assessed by the investigator

    Time frame: From the beginning of randomization to the time of treatment ended ,about 30 months after first dose

07

Study locations

2 sites
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
    • Yupei Zhao · Principal investigator
    • Wenming Wu · Principal investigator
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality, China
    • Baiyong Shen · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2030, 49 months later.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's planned 49 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2026
First posted
Oct 28, 2026
StartEst.
Oct 2026
Primary completionEst.
Nov 30, 2030
CompletionEst.
Dec 30, 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07900789
Responsible party
Sponsor
First posted
Oct 28, 2026
Start date
Oct 2026 (estimated)
Primary completion
Nov 30, 2030 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Meng Qin
Contact
meng.qin.mq8@hengrui.com
+86 0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: KRAS G12D Inhibitor HRS-4642 · Adebrelimab · Gemcitabine · Paclitaxel

Start the discussion